Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Regeneron

EyePoint's drug for age-related eye disease fails late-stage trial, shares tank 70%

EyePoint's experimental drug Duravyu failed a late-stage trial for a serious eye disease. The company's shares dropped significantly after the disappointing trial results were announced. This failure impacts EyePoint's goal to compete with Regeneron's successful Eylea treatment. Analysts suggest investors will await further study confirmation for the drug's viability. EyePoint…

The Economic Times

Meet Connor Hill, the 17-year-old Pennsylvania student who wrote a computer program to classify noble polyhedra; he proved there are 146 isolated examples and won $250,000

Connor Hill triumphed in the competition with his exceptional algorithm for classifying noble polyhedra, discovering two infinite families alongside 146 distinct shapes. Edward Kang's AI tool for autism screening claimed the second position, and Iris Shen's innovative blood cancer research involving clams took third place. Additionally, Regeneron expressed their commitment…

The Times of India

About 1 in 7,000 People Carry a Broken Gene That Appears to Keep Them Lean, and Drugmakers Noticed

A Nature study of more than 1 million people found rare FNIP1 variants associated withFNIP1 gene, metabolic health genetics, liver fat, TG:HDL ratio, cardiometabolic disease, Regeneron Genetics Center, obesity genetics less liver fat, lower blood sugar, and 60% lower odds of disease.

Medical Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Here's What to Expect From Regeneron Pharmaceuticals’ Next Earnings Report

Regeneron Pharmaceuticals is set to report its second-quarter results this month, with analysts expecting a double-digit decline in earnings year over year.

Barchart

What to know about the Bundibugyo virus, a species of Ebola causing an outbreak in Congo

A rare Bundibugyo virus outbreak in Congo, with over 200 deaths, lacks specific treatments or vaccines, complicating response efforts. While potentially less lethal than other Ebola strains, its high mortality rate necessitates basic public health measures. Promising vaccine and therapy candidates are undergoing clinical trials.

The Economic Times

US stocks today: Nasdaq falls as technology stocks slide, Treasury yields climb

US stocks closed mixed as Nasdaq slipped due to profit booking and rising Treasury yields, while Dow edged higher. Oil prices surged on supply disruption fears but later eased after geopolitical comments. Energy stocks outperformed, Nvidia earnings are awaited, and Regeneron fell after a failed drug trial result.

The Economic Times

Regeneron Sinks 10% on Failed Phase 3 Melanoma Trial. What Comes Next for REGN Stock.

Regeneron stock sinks as fianlimab Phase 3 trial fails to meet primary endpoint. But RBC continues to see significant upside in REGN shares from here.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Appian Pitches Reliable AI, $825M Revenue Goal and Bigger Buyback at Investor Day

Appian (NASDAQ:APPN) executives used the company’s Investor Day 2026 in New York to frame the software maker as a provider of “complex process automation” for regulated industries and as a platform for making artificial intelligence more reliable in enterprise workflows. Chief Financial Officer Ser

MarketBeat

CRISPR Genome Editing and the Future of Down Syndrome Treatment

The ethics of using safe gene therapies to improve the health and cognition of Down syndrome children and adults.

Reason

Trump Appears to Doze Off During Live Oval Office Event as Video of Him Mocking 'Sleepy Joe' Biden Resurfaces

President Trump, 79, appeared to nod off during a live Oval Office event, sparking renewed scrutiny over his health. The incident contrasts with his past criticism of Biden's on-camera drowsiness.

International Business Times UK

'A landmark moment for the field': FDA approves first-ever gene therapy for inherited deafness

A gene therapy made by Regeneron is the first treatment of its kind approved for genetic hearing loss.

LiveScience

Trump will unveil a deal with Regeneron to lower drug prices

President Donald Trump is set to announce a deal with Regeneron to lower drug costs as part of the White House's effort to lower drug prices

The Independent UK

Trump cuts drug price deal with Regeneron

Regeneron is the last of 17 companies the administration pressed to commit to the "most favored nation" policy.

Axios

Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Tuesday reported third-quarter adjusted earnings of $11.83 per share, down 5% year-over-year, beating the consensus of $9.59.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Regeneron's Gene Therapy Shows Significant Gains In Genetic Hearing Loss

On Sunday, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) unveiled updated data from its investigational gene therapy DB-OTO for profound genetic hearing loss caused by variants of the otoferlin (OTOF) gene.

Benzinga

Regeneron's Libtayo Gains FDA Approval To Reduce Recurrence Risk In Skin Cancer Patients

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ:REGN) PD-1 inhibitor Libtayo (cemiplimab-rwlc) as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation.

Kiplinger

The Best Biotech ETFs to Buy

Biotech ETFs offer investors exposure to the most innovative and growth-oriented industry within the traditionally defensive healthcare sector.

Benzinga

FDA Expands Use Of Regeneron's Evkeeza To Infants With Rare Cholesterol Disorder

The U.S. Food and Drug Administration (FDA) on Friday approved Regeneron Pharmaceuticals, Inc.’s (NASDAQ: REGN) Evkeeza (evinacumab-dgnb) ANGPTL3 antibody as an adjunct to diet and exercise and other lipid-lowering therapies for the treatment of children from age 1 to less than 5 years old with homozygous familial hypercholesterolemia (HoFH).

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Regeneron Touts Positive Data From Phase 3 Study In Patients With Ultra-Rare Genetic Disorder

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported positive results from its Phase 3 OPTIMA trial of garetosmab in adults with fibrodysplasia ossificans progressiva (FOP), meeting the study's primary endpoint.

Benzinga

What's Happening With Regeneron Pharmaceuticals Stock On Monday?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) revealed data from Phase 3 trials in adults with moderate-to-severe cat or birch allergies on Monday. Both trials met their respective primary and key secondary endpoints.

Barchart

How Is Regeneron’s Stock Performance Compared to Other Pharma Stocks?

Regeneron Pharmaceuticals has significantly underperformed the broader pharma space over the past year, yet analysts remain optimistic about the stock’s prospects.

Benzinga

Regeneron Advances In Rare Disease Race With Positive Autoimmune Muscle Disorder Trial Data

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Tuesday shared data from the Phase 3 NIMBLE trial assessing investigational cemdisiran monotherapy in adults with generalized myasthenia gravis (gMG).

Barchart

Worried About a Market Crash? Here Are 3 Stocks That ‘Big Short’ Star Michael Burry Loves Here.

Here are three top stocks that the ‘Big Short’ star Michael Burry owns in Q2 of 2025. Are UNH, REGN, and LULU undervalued right now?

Benzinga

These Analysts Increase Their Forecasts On Regeneron Pharmaceuticals After Better-Than-Expected Earnings

On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported upbeat second-quarter earnings.

Benzinga

Regeneron's Pipeline Hit By Catalent Delays, But Dupixent Shines

On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% year-over-year, beating the consensus of $8.57.

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.